Aug 2026· Frontiers in Immunology· Vol 17· 0 citations· 215 references
Medicine
TL;DR
The types and properties of nanomaterials used to induce transplantation tolerance, systematically discusses their payload categories and immunoregulatory mechanisms, and delineates key delivery strategies and in vivo mechanisms are summarized.
Abstract
Organ transplantation is the primary therapeutic approach for patients with end-stage organ failure. However, challenges such as transplant rejection, the toxic side effects of long-term systemic immunosuppression, and substantial economic burdens remain pressing issues in clinical practice. The goal of inducing donor-specific transplantation tolerance is considered the most effective strategy to address these problems. Conventional tolerance-inducing strategies, including hematopoietic chimerism establishment, costimulatory signal blockade, and regulatory cell therapy, are often hampered by key limitations such as myeloablative toxicity, resistance from memory T cells, high costs associated with ex vivo cell expansion, and poor in vivo stability. This review summarizes the types and properties of nanomaterials used to induce transplantation tolerance, systematically discusses their payload categories and immunoregulatory mechanisms, and delineates key delivery strategies and in vivo mechanisms. Furthermore, it analyzes current challenges and bottlenecks faced by nanodelivery systems. Finally, future perspectives on optimizing and translating these systems into clinical applications are proposed, providing valuable insights for developing safe, precise, and efficient strategies for transplantation tolerance induction.
This work categorizes the classes of nanomedicines and their specific delivery routes in LT, mapping these technologies onto clinical bottlenecks and critically appraising each platform to frame a path toward clinical translation.
A. Maskos, Aravind Krishnan, Matthew M. Duda et al.· American Journal of Transpla...· 0 citations
Key challenges related to the biodistribution, activation, and persistence of modified T cells are highlighted, with an emphasis on the potential of these strategies for treating not only blood cancers but also solid tumors, autoimmune diseases, and beyond.
Jens B. Simonsen, Viktor T. Lemgart, J. Kulkarni et al.· Advanced Drug Delivery Revie...· 1 citation
ABSTRACT Lung transplantation is the only long‐lasting life‐saving treatment for patients with end‐stage pulmonary disease, but the ever‐growing shortage of suitable donor organs leads to high mortality rates of the afflicted patients. Xenotransplantation, the transplantation of organs across species, has emerged as a...
N. Roters, Niveditha Varma, R. Ramm et al.· Xenotransplantation· 0 citations
Solid organ xenotransplantation is moving into early clinical use, whereas living xenogeneic cells and tissues are being developed for distinct therapeutic tasks. Product-based discussions can obscure differences in required functional duration, immune exposure, consequences of product loss, and acceptable treatment bu...
H. Hara· Clinical transplantation and...· 0 citations
This review highlights key engineering strategies enabling in vivo CAR T-cell generation, summarizes emerging clinical research and development, and discusses future opportunities for expanding in vivo CAR T-cell therapies as scalable immunotherapy platforms.
Janani Gopalakrishnan, Bhagyashri Rathod, Sachin Puri· International Immunopharmaco...· 0 citations
The mechanisms, current clinical landscape, and major challenges of in vivo CAR-T cell therapy are summarized and existing optimization strategies applicable to this therapy are systematically outlined.
Yi-Kun Li, Feng-Ling Wang, Jia-Qian Li et al.· Biochemical Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.